Abstracts

130 – Resistance Analyses of the PURPOSE Studies Through the End of the Randomized Blinded Phase

Background Twice-yearly subcutaneous lenacapavir (LEN) is a HIV-1 capsid (CA) inhibitor approved for HIV pre-exposure prophylaxis (PrEP) based on efficacy and safety from the PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) Phase 3 studies. The primary analyses demonstrated that acquisition of HIV while receiving LEN and emergent resistance during the studies were rare. Here, we…

131 – RCT of Dynamic Choice to Provide Oral PrEP to Postpartum South African Women

Background Postpartum women are at elevated risk of HIV acquisition and vertical transmission. Oral PrEP reduces HIV risk, though poor adherence and discontinuation reduce effectiveness. Providing dynamic choice in PrEP delivery within clinics and communities may improve effective PrEP use, however data among postpartum women are few. Methods We enrolled postpartum women without HIV who…

133 – A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART

Background Antiretroviral therapy (ART) suppresses HIV-1 replication but does not eradicate long-lived reservoir cells. The envelope glycoprotein (Env) is the only viral antigen displayed on the surface of infected cells, making it the immunotherapy target of choice for cure strategies. While current latency-reversing agents (LRAs) induce p24 expression, their ability to stimulate Env expression remains…

134 – Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B

Background Therapeutic levels of broadly neutralizing antibodies (bNAbs) can sustain undetectable HIV viraemia. We investigated if post-bNAb control persists after an ART-protected ‘wash-out’ period. In the RIO trial, Arm B participants initially received placebo during a first analytical treatment interruption (ATI-1). Following rebound, participants resumed ART and were offered 3BNC117-LS and 10-1074-LS, and later underwent…

135 – Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control

Background Interruption of antiretroviral therapy (ART) typically leads to viral rebound within weeks in people with HIV-1. Post-intervention controllers (PICs) control viremia without ART after a therapeutic intervention. We characterised three PICs with suppressed viral load for >6.5 years (ID107), >7.5 years (ID9254) and 2.5 years (ID142) following HIV-1 broadly neutralising antibody administration.  Methods The…

137 – CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption

Background The primary barrier to HIV cure is the latent viral reservoir, which persists despite antiretroviral therapy (ART). HIV activation could improve reservoir clearance, but previous approaches had unfavorable safety profiles. Interleukin-15 (IL-15), an immune modulatory cytokine, can activate HIV but has shown toxicity due to NK and CD8+ expansion. We developed CD4-targeted IL-15 (GS-huCD4-IL15) and…

138 – Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones

Background The long-term persistence of HIV-1 infected CD4+T cell clones is a major barrier to cure strategies. However, mechanisms contributing to their ability to survive long-term and resist immune elimination are poorly understood. Here, we comprehensively characterized the somatic mutation landscape of HIV-1 infected and uninfected CD4+T cell clones isolated from five ART-treated persons living with…